icaria-MM: sarclisa + Pd

icaria-MM Patient
Profiles

Treating with sarclisa + pomalidomide and
dexamethasone (Pd) as early as first relapse
1

Current patient information

68 years of age

Cytogenetic risk
High: t(4;14)
ECOG PS 0
Cardiovascular comorbidities
ECG shows EF 45%,
uncontrolled hypertension
Older age

Diagnosis

Diagnosed 3 years ago after work-up for fatigue revealed anemia

1st line

VRd induction → ASCT → bortezomib and lenalidomide maintenance (CR for 30 months posttransplant)

1st relapse

Peripheral neuropathy; relapsed with new lesion in humerus found on MRI

2nd-line treatment considerations for Laura

  • High cytogenetic risk
  • Cardiovascular comorbidities
  • Double refractory to lenalidomide and bortezomib
  • Candidate for a triplet combination that includes a multimodal anti-CD38 mAb and a third-generation IMiD®

consider sarclisa + Pd as early as first relapsefor patients with high cytogenetic risk and patients with cardiovascular
comorbidities1

PFS in the intent-to-treat population1

  • mPFS: 11.53 months with SARCLISA + Pd (n=154) vs 6.47 months with Pd alone (n=153), HR=0.596 (95% CI: 0.44, 0.81; P=0.0010)

This is a hypothetical case study portrayed by an actor and should not substitute a healthcare provider's decision.

ASCT=autologous stem cell transplant; CR=complete response; ECG=electrocardiogram; ECOG PS=Eastern Cooperative Oncology Group performance status; EF=ejection fraction; IMiD=immunomodulatory drug; mAb=monoclonal antibody; mPFS=median progression-free survival; MRI=magnetic resonance imaging; PFS=progression-free survival; RRMM=relapsed or refractory multiple myeloma; VRd=bortezomib, lenalidomide, dexamethasone.

PFS results in patients with high cytogenetic risk
and patients refractory to lenalidomide

In icaria-MM, 20% of patients had high cytogenetic risk* and 93%
were refractory to lenalidomide1

PFS in patients with high cytogenetic risk2,3

34%
Reduction in the risk of
disease progression

HR=0.66 (95% CI: 0.33, 1.28)

PFS in patients refractory to lenalidomide4

41%
Reduction in the risk of
disease progression

HR=0.59 (95% CI: 0.43, 0.82)

See the full icaria-mm patient subgroup data

Study limitations

Prespecified subgroup analysis; subgroups were not powered to show differences between treatment arms.

*Cytogenetics by central lab; cutoff 50% for del(17p), 30% for t(4;14) and t(14;16).3

Expert review

Join Dr Noa Biran and Dr Binod Dhakal as they discuss the patient types in which SARCLISA was studied

Watch the video.

Patient Profile Brochure

Review profiles of potential candidates for treatment with SARCLISA, including patient types with renal impairment and high cytogenetic risk

Download the resource.

Current patient information

78 years of age

Cytogenetic risk
Standard
ECOG PS 1
Elderly
Renal function
(eGFR)

48 mL/min/1.73 m2

Diagnosis

Diagnosed ~3.5 years ago after presenting with anemia, moderate renal insufficiency, mild hypercalcemia, and severe osteoporosis; transplant ineligible

1st line

VRd induction → lenalidomide maintenance (VGPR for 36 months); developed persistent peripheral neuropathy during induction

1st relapse

Relapse confirmed after consecutive labs showed increase of M-protein and light chains, recurrence of hypercalcemia, and reappearance of renal insufficiency

2nd-line treatment considerations for Ben

  • Elderly
  • Impaired renal function
  • Refractory to lenalidomide
  • Developed neuropathy from prior bortezomib treatment
  • Candidate for a triplet combination that includes a multimodal anti-CD38 mAb and a third-generation IMiD®

consider sarclisa + Pd as early as first relapsefor elderly patients and patients with impaired renal function1

PFS in the intent-to-treat population1

  • mPFS: 11.53 months with SARCLISA + Pd (n=154) vs 6.47 months with Pd alone (n=153), HR=0.596 (95% CI: 0.44, 0.81; P=0.0010)

This is a hypothetical case study portrayed by an actor and should not substitute a healthcare provider's decision.

ECOG PS=Eastern Cooperative Oncology Group performance status; eGFR=estimated glomerular filtration rate; IMiD=immunomodulatory drug; mAb=monoclonal antibody; M-protein=monoclonal protein; mPFS=median progression-free survival; PFS=progression-free survival; RRMM=relapsed or refractory multiple myeloma; VGPR=very good partial response; VRd=bortezomib, lenalidomide, dexamethasone.

PFS results in elderly patients and
patients with impaired renal function

In icaria-MM, 20% of patients were elderly (≥75 years) and
36% had impaired renal function3*

PFS in elderly patients (≥75 years)2,3

52%
Reduction in the risk of
disease progression

HR=0.48 (95% CI: 0.24, 0.95)

PFS in patients with renal impairment2,3

50%
Reduction in the risk of
disease progression

HR=0.50 (95% CI: 0.30, 0.85)

See the full icaria-mm patient subgroup data

Study limitations

Prespecified subgroup analysis; subgroups were not powered to show differences between treatment arms.

*eGFR <60 mL/min/1.73 m2.1

Expert review

Join Dr Noa Biran and Dr Binod Dhakal as they discuss the patient types in which SARCLISA was studied

Watch the video.

Patient Profile Brochure

Review profiles of potential candidates for treatment with SARCLISA, including patient types with renal impairment and high cytogenetic risk

Download the resource.
Back to topTop